Elicera Therapeutics

Elicera Therapeutics AB is a clinical stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments.

[BioStock @BioStock_SWE]

Eliceras vd: ”iTANK-partnering intensifieras”

#BioStockSwe #LifeScience @EliceraTx https://t.co/RBALFQycdO

[Elicera Therapeutics @EliceraTx]

Press Release: Elicera Therapeutics’ co-founders receive additional grants totalling 7,65 MSEK from the Swedish Cancer Society to support #CARTresearch
Read the press release:
https://t.co/4leA93bKgr

[BioStock @BioStock_SWE]

@EliceraTx medgrundare får ytterligare bidrag på totalt 7,65 Mkr från Cancerfonden för att stödja CAR T-forskning
https://t.co/rBvdENmzyL
#BioStockSwe #LifeScience

[BioStock @BioStock_SWE]

@EliceraTx tecknar det första internationella samarbetsavtalet kring iTANK-plattformen med ett spanskt forskningsinstitut
https://t.co/4KDoDMJ60h
#BioStockSwe #LifeScience

[Elicera Therapeutics @EliceraTx]

Press Release:

- Elicera Therapeutics enters first international collaboration involving the iTANK platform with a Spanish research institution -

https://t.co/NaEyanVXho

#immunotherapy

[Elicera Therapeutics @EliceraTx]

We are delighted that the Swedish Society for Gene and Cell Therapy (SSGCT) has awarded a PhD thesis written by our company co-worker Jing Ma best of the year 2021 in Sweden!

#Immunotherapy

[BioStock @BioStock_SWE]

@EliceraTx stärkte den finansiella ställningen under Q2
#BioStockSwe #Lifescience #Elicera https://t.co/nEyiFj3yAj

[Elicera Therapeutics @EliceraTx]

Our Q2 report is now available and it’s been a busy and successful year for us so far. Head to our website for the full report!
https://t.co/KvHdxjZ18d
#Immunotherapy

[BioProcess Online @BioProcessOL]

Check out the latest edition of the Bioprocess Online newsletter featuring @EliceraTx's Jamal El-Mosleh, @PyxisOncology's Lara Sullivan's appearance on the #BusinessOfBiotech #podcast, and industry insight from our partners.

#bioprocessing #biopharma

https://t.co/xilD3x3Kks

[Cell&Gene @_CellandGene]

Immuno-oncology is a vast and promising field within cancer therapeutics, however, there is still a significant need for better treatments for solid tumors.

By Jamal El-Mosleh, Co-founder and CEO, @EliceraTx

https://t.co/AAufA7Gzyz

[Cell&Gene @_CellandGene]

Immuno-oncology is a vast and promising field within cancer therapeutics, however, there is still a significant need for better treatments for solid tumors.

By Jamal El-Mosleh, Co-founder and CEO, @EliceraTx

https://t.co/AAufA7Yaq7

[BioStock @BioStock_SWE]

Elicera Therapeutics tilldelas 2,5 miljoner Euro i EU-finansiering för att fullt ut finansiera en klinisk fas I/II-studie med sin CAR T-cellsterapi, ELC-301
https://t.co/M11v60SoTT
#BioStockSwe #lifescience @EliceraTx

[Elicera Therapeutics @EliceraTx]

PRESS RELEASE:
Elicera Therapeutics receives 2.5 million Euros in EU funding to fully finance a clinical phase I/II-trial with its CAR T-cell therapy, ELC-301 https://t.co/UDWZcZyEg9

[Elicera Therapeutics @EliceraTx]

Missed us at the SWECARNET Education Day last week?

Listen to what our Scientific Advisor Professor Gunilla Enblad had to say about the future of #cartcelltherapy in our recorded interview.

https://t.co/qfdbBPu2Wz

#immunotherapy

[BioStock News @BioStock_News]

@EliceraTx successfully concludes preclinical proof-of-concept studies for oncolytic virus ELC-201 confirming the proposed mode-of-action
https://t.co/uR76m6Zvdt
#BioStockSwe #lifescience #Elicera

[Elicera Therapeutics @EliceraTx]

We're delighted to announce that we have successfully concluded preclinical proof-of-concept studies for our oncolytic virus ELC-201, confirming the proposed mode-of-action. https://t.co/LYiVskRKPy #Immunotherapy

[BioStock @BioStock_SWE]

BioStock Studio: @EliceraTx’s immuno-oncology platform iTANK reaches high-impact journal #BioStockSwe #lifescience https://t.co/nx2codWRHR

[BioStock @BioStock_SWE]

BioStock Studio: @EliceraTx publicerar artikel om iTANK i högt rankad tidskrift #BioStockSwe #lifescience https://t.co/RLP66SKzxn

[Elicera Therapeutics @EliceraTx]

Below is the direct link to our article just published in @NaturePortfolio's Biomedical Engineering journal

https://t.co/MIGcscYFUA

Learn more about our iTANK-platform and data indicating its universal compatibility with other #CARTcell therapies.

[Elicera Therapeutics @EliceraTx]

We are attending @EBDGroup's BIO-Europe Spring, taking place virtually March 28-31.

Visit the event website and schedule a partner meeting with our team or contact us directly.

[email protected]

#immunooncology #immunotherapy #bioeuropespring

https://t.co/3HOHZK9tc6